v3.26.1
Note 2 - Significant Accounting Policies - Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Cost of sales $ 12,475 $ 12,301 $ 22,899 $ 22,857
Research and development 18,895 15,452 38,690 29,315
Stock-based compensation     3,849 3,654
Total operating costs and expenses 48,917 45,800 97,559 87,823
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member]        
Cost of sales 12,475 12,301 22,899 22,857
General and administrative 5,087 6,538 11,488 12,718
Commercialization 11,280 10,517 22,163 20,707
Operating costs and expenses 46,964 44,172 93,710 84,170
Stock-based compensation 1,953 1,628 3,849 3,654
Total operating costs and expenses 48,917 45,800 97,559 87,823
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Clinical Research [Member]        
Research and development 10,664 7,679 22,108 14,093
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Medical Affairs [Member]        
Research and development 1,141 1,631 2,480 2,784
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Other Research and Development [Member]        
Research and development [1] $ 6,317 $ 5,506 $ 12,572 $ 11,012
[1] Other research and development expense includes regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.